Amphastar Pharmaceuticals, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +14.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.51 | $0.80 | +56.9% | Beat | Q2 FY26 call |
| Q1 FY26 | $0.62 | $0.26 | -58.1% | Miss | |
| Q4 FY25 | $0.89 | $0.61 | -31.5% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.73 | $0.83 | +13.7% | Beat | |
| Q2 FY25 | $0.64 | $0.75 | +17.2% | Beat | |
| Q1 FY25 | $0.58 | $0.61 | +5.2% | Beat | |
| Q4 FY24 | $0.80 | $0.83 | +3.8% | Beat | |
| Q3 FY24 | $0.93 | $0.87 | -6.5% | Miss | |
| Q2 FY24 | $0.75 | $0.85 | +13.3% | Beat | |
| Q1 FY24 | $0.73 | $0.93 | +27.4% | Beat | |
| Q4 FY23 | $0.84 | $0.81 | -3.6% | Miss | |
| Q3 FY23 | $0.67 | $1.08 | +61.2% | Beat |
Back to AMPH overview · AMPH holders · AMPH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.